Skip to main content
OpenTrials
Completed

NCT Number: NCT03009500

Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain

The purpose of this study is to evaluate three different injectable solutions used to block ankle nerves to manage ankle pain. The current standard of medical care is to inject a combination of local anesthetics and steroids around injured nerves. There is evidence that injection of local anesthetic (without the steroid) can calm the injured nerve and provide pain relief from a few days up to a few months. Injection of sterile salt water also has the potential to provide pain relief by breaking scar tissue around the nerve thereby relieving compression. Injections of local anesthetic and steroids around injured nerves have been used for many years to provide relief of pain but the specific reason is not well known for this benefit.

There are three possibilities: 1) Steroids can reduce inflammation and calm the nerves, 2) local anesthetics can have similar actions but with shorter duration (few days), and 3) injection of any solution can break scarring around an injured/compressed nerve.

The study will compare pain relief and possible adverse effects from these three different solutions. This study will help provide definitive answers regarding pain relief and possible adverse effects of the three solutions. This, in turn, will determine the best possible option for injection in patients with nerve-related injury pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

About this study

This project is a randomized controlled trial with the aim of comparing efficacy of image (ultrasound)-guided administration of perineural combination of steroids and local anesthetic (current standard of care) against perineural local anesthetic (LA) or saline in providing sustained analgesic benefit in people with chronic neuropathic pain (NP) of the foot and ankle.

The study design will be multi-center, prospective, concealed, blinded, parallel group trial with three groups, block randomization (blocks of six participants) and allocation in a 2:2:2 ratio. Study participants and outcome evaluators will be blinded to treatment assignments.

Participants will be randomly assigned to one of the three groups to receive two US-guided injections (at an interval of one to two weeks) of one of the following around one or more of the five nerves innervating the foot and ankle:

The initial procedure will be repeated after one to two weeks unless clinical circumstances dictate otherwise (that is, the patient declined a second injection because of increase in pain or satisfaction with pain relief). The rationale for the repeat procedure is to allow possible benefit from a cumulative effect of the procedures and/or the injectates. Between the first injection and first follow-up visit, no patient will be allowed any additional therapeutic interventions. Nerves to be targeted by the injection will be decided by the treating physician based on area of the foot and ankle that displays features of neuropathic pain. Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of LA (2% lidocaine) at each of the injection sites. This will reduce discomfort of the study participants from the injections. The subcutaneous LA will also cause numbness of the skin and this will ensure blinding of participants to their group allocation. Two ultrasound-guided procedures will be performed at weekly intervals over two weeks. The US-guided technique for performing these procedures has been described in previous studies from our center.22 Conservative measures (oral analgesics, physiotherapy) will continue during the study. Fasting blood glucose will be measured at baseline and at one month following the interventions. Systolic and diastolic blood pressure (with participant sitting for at least 5 minutes prior to the measurement) values will be recoded as a mean of three consecutive readings at baseline and at one month following the interventions. Cross-sectional area (CSA) of tibial nerve at 3 cm proximal to cephalad edge of medial malleolus will also be measured prior to the first procedure and prior to the second procedure in participants with pain in distribution of the tibial nerve. Change in CSA (if any) will be correlated with analgesic response to perineural injections because decrease in CSA may indicate reduction in edema of the nerve.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pain in foot in neuro-anatomically congruent location following trauma (including surgery) for more than three months
  • Physician-reported DN4 scoring confirming neuropathic pain (score >3/10)
  • Average intensity of pain more than 3/10 on numerical rating score
  • Failed trial of appropriate doses of first line medications for neuropathic pain (anticonvulsants and/or antidepressants) for six weeks

Exclusion criteria

  • Age < 18 or Age > 80 years
  • Perineural or intra-articular steroid injections in the last 6 months
  • Allergy to local anesthetics or steroids
  • Ongoing litigation issues related to the patient's pain
  • Pregnancy
  • Coagulopathy or systemic infection
  • Peripheral neuropathy or myopathy, central neuropathic pain (e.g. post-stroke pain)
  • Infection in the ankle or foot
  • An unstable medical or psychiatric condition
  • Significant catastrophizing as indicated by pain catastrophizing scale (PCS) score equal to or more than 30/52.

Treatment and study plan

Bupivacaine

Drug

Other names: Marcaine

Depo-Medrol Injectable Product

Drug

Other names: Methylprednisone

Saline (Sodium Chloride) solution

Other

Lidocaine

Drug

Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections

Primary outcomes

  1. Determination of Numerical Rating Scores (NRS) (range 0-10) for foot and ankle pain

    Time frame: One month after intervention

Secondary outcomes

  1. Measuring NRS (range 0-10) for foot and ankle pain

    Time frame: Three months after intervention compared to pre-intervention

  2. Measuring changes in the PCS (Pain Catastrophizing Scale) Questionnaire

    Time frame: One month and three months after intervention compared to pre-intervention

  3. Measuring changes in the Douleur Neuropathique (DN4) Questionnaire

    Time frame: One month and three months after intervention compared to pre-intervention

  4. Measuring change in the NPSI (Neuropathic Pain Symptom Inventory) Questionnaire

    Time frame: One month and three months after intervention compared to pre-intervention

  5. Measuring change in the Anxiety and Depression component scores on the Hospital Anxiety and Depression Scale (HADS)

    Time frame: One month and three months after intervention compared to pre-intervention

  6. Measuring change in Depression scores on the Patient Health Questionnaire (PHQ-9)

    Time frame: One month and three months after intervention compared to pre-intervention

  7. Measuring change in Brief Pain Inventory interference with activities (BPI-I) score

    Time frame: One month and three months after intervention compared to pre-intervention

  8. Measuring change in Short Form-12 (SF-12) score

    Time frame: One month and three months after intervention compared to pre-intervention

  9. Measuring change in Lower Extremity Function Score (LEFS)

    Time frame: One month and three months after intervention compared to pre-intervention

  10. Measuring change in pain (cold pain and heat pain) thresholds as determined by quantitative sensory testing (QST)

    Time frame: One month and three months after intervention compared to pre-intervention

  11. Measuring change in sensory (cold and hot detection) thresholds as determined by quantitative sensory testing (QST)

    Time frame: One month and three months after intervention compared to pre-intervention

  12. Measurement of the cross-sectional area of tibial nerve for neural edema between interventions

    Time frame: One month and three months after intervention compared to pre-intervention

  13. Measuring incidence of adverse effects

    Time frame: One month and three months after intervention compared to pre-intervention

    • Hyperglycemia (change in blood glucose levels) and hypertension (change in blood pressure levels)
    • Infections at the injection site, skin discolouration or atrophy at the injection site, fractures, and evidence of myopathy

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Official study title

A Multi-center Randomized Controlled Trial of Efficacy and Safety of Perineural Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain: The Resperist Study

Acronym: RESPERIST

Important dates

Study start
2017
Primary completion
2018
Study completion
2019
First posted
Jan 4, 2017
Registry last updated
Mar 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.